A Clearinghouse for Information about Blood Clots (DVT/)PE) and Clotting Disorders (thrombophilia) provided as a public service by the University of North Carolina Blood Research Center

Tag: PE

  • Incidentally Discovered DVT, PE or Other Clots

    General comments CT or MRI scans will occasionally detect an incidental iliofemoral DVT, PE or intra-abdominal thrombosis (IVC, portal, splenic, mesenteric or renal vein). This is particularly common in cancer patients undergoing staging CT scans. When such an incidental, asymptomatic venous thromboembolism (VTE) is discovered, the question arises whether the patient should be treated with…

  • Incidentally Discovered Blood Clots

    General comments CT scans and MRI scans are often done in medicine, for a variety of reasons.  Every so often such a scan will detect a blood clot in a patient who has no symptoms from the clot. This is referred to as an “incidental VTE”  (VTE = venous thromboembolism, i.e. clot in a vein)…

  • DVT and PE: How Long to Treat With Anticoagulants?

    Explanation for Patients The complex topic of “Length of Anticoagulant Treatment” for patients with VTE  is being addressed in a blog entry written for patients, found on the Clot Connect patient education blog (here). For the Health Care Professional Well respected treatment guidelines exist [ref 1,2].

  • DVT and PE: How Long to Treat with “Blood Thinners”

    What Kind of Clot did You Have? If you have had a blood clot in your legs or your lung (pulmonary embolism=PE), you will wonder how long you should stay on a “blood thinner”. The decision depends on a number of factors which will be discussed below.

  • Apixaban (Eliquis®) – Another New Oral Anticoagulant

    Good news.  Another one of the new oral anticoagulants in development,  Apixaban (Eliquis®), has moved forward.  On May 20th, 2011, the European Medicines Agency (EMA) approved Eliquis® for DVT prevention after orthopedic surgery (hip and knee replacement) in the 27 countries of the European Community. In the U.S., however, Eliquis® is still some way away from getting FDA approval

  • Apixaban (Eliquis): Another New Oral “Blood Thinner”

    Good news. Another one of the new oral “blood thinners” in development,  Apixaban (Eliquis®), has moved forward. On May 23rd, 2011 the European Medicines Agency (EMA) approved Eliquis® for marketing in the 27 countries of the European Community for DVT prevention after orthopedic surgery (hip and knee replacement). In the U.S., Eliquis® is not yet FDA approved, and still…

  • What Causes Clots? – A Family Study

    Background It is known that the risk for blood clots in the leg (DVT) and lung (PE) is partly inherited. Some genes that increase the risk for DVT and PE are known (e.g. factor V Leiden, the factor II 20210 mutation, protein, protein C, S and antithrombin mutations). However, it is suspected that many other and,…

  • Athletes and DVT + PE

    Background Many people think of DVT and PE as a problem occurring in elderly people, but not in young and apparently healthy individuals. While it is certainly true that they occur more commonly in the elderly and in non-athletic overweight individuals, they can, nevertheless, happen in young, normal weight, and athletic people.